Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB versus RETEVMO.
NILOTINIB vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Binds to inactive conformation of ABL kinase, preventing ATP binding and substrate phosphorylation.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
300 mg orally twice daily for newly diagnosed chronic phase CML; 400 mg orally twice daily for resistant or intolerant CML. Take on an empty stomach (no food for 2 hours before and 1 hour after).
160 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateNilotinib + Digoxin
"Nilotinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilotinib + Digitoxin
"Nilotinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilotinib + Deslanoside
"Nilotinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilotinib + Acetyldigitoxin
"Nilotinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 17 hours (range 14-20 hours), supporting twice-daily dosing.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (93% of absorbed dose) via biliary excretion; renal excretion accounts for <1% of unchanged drug.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor